Compared with monotherapy, the combination therapy with ETO and siVEGF performed excellent and long-term inhibition of tumor proliferation and angiogenesis in orthotopic NSCLC with low biotoxicity. The gene discussed is RUNX1T1; the disease is neoplasm.